

Haematologica  
HAEMATOL/2018/195123  
Version 3

A phase II/III randomized, multicenter trial of Prednisone /Sirolimus vs  
Prednisone/Sirolimus/Calcineurin Inhibitor for treatment of chronic  
graft-versus-host disease: BMT CTN 0801

Paul A Carpenter, Brent R Logan, Stephanie J Lee, Daniel J Weisdorf,  
Laura Johnston, Luciano J Costa, Carrie L Kitko, Javier  
Bolaños-Meade, Stefanie Sarantopoulos, Amin M Alousi, Sunil  
Abhyankar, Edmund K Waller, Adam Mendizabal, Jiayi Zhu, Kelly A  
O'Brien, Aleksandr Lazaryan, Juan Wu, Eneida R Nemecek, Steven Z  
Pavletic, Corey S Cutler, Mary M Horowitz, and Mukta Arora  
Collaborative Groups: on behalf of the Blood and Marrow Clinical Trials  
Network)

Disclosures: M.M.H., C.K.L., L.J.C., M.A., A.L., L.J., S.P., B.R.L., A.M.A., J.W., E.K.W.,  
A.M., J.Z., and K.A.O. have no conflicts of interest to disclose. E.N. is an advisory board  
member at Novartis and a consultant for Medac GmbH. S.A. is a consultant and member  
of the speaker's bureau at Therakos. S.J.L. is a consultant for Incyte, Pfizer, and Amgen, is  
an honorary speaker for Mallinckrodt, and a member of the Board of Directors for the  
American Society of Hematology. P. A.C. is a consultant for Mallinckrodt, Fate  
Therapeutics, and Incyte. F.J.-B. has received honoraria from Incyte as part of a DSMB.  
C.S.C. is a consultant for Bristol-Myers Squibb and Incyte. S.S. has a research grant from  
Gilead studying the Syk inhibitor, Entospletinib, in a mouse model and has served as a  
consultant and advisor to Gilead and Pharmacyclics (Entospletinib and Ibrutinib for chronic  
GVHD). D. W. has research support from Incyte and Alexion, and is a consultant for Incyte,  
AbGenomics, Pharmacyclics, and CSL Behring.

Contributions: Contribution: P.A.C., M.A., and B.R.L. designed the study protocol and wrote  
the paper; P.A.C, M.A. and A.M. were senior advisors in the design and conduct of the  
study; A.M.A, J.B.-M, C.S.C, M.M.H, L.J.C, S.J.L, D.J.W advised on specific to study  
design elements; P.A.C, M.A., J.B.-M., S.Z.L., L.J.C., C.L.K., L.J., S.J.L. and A.L. formed  
the Endpoint Review Committee; P.A.C., S.J.L., D.J.W., L.J., L.J.C., C.L.K., J.B.M., S.S.,  
A.M.A, M.M.H, S.A., E.K.W, A.L., E.R.N., and M.A. enrolled and cared for patients; K.A.O.,  
J. Z., J. W., and B.R.L. contributed to study coordination, data compilation, and statistical  
analysis; P. A. C. and J. Z. drew the figures; all authors reviewed and provided insightful  
comments to complete and approve the manuscript.